What Is Triptorelin Used For? Approved Uses, Per the Label

What triptorelin is

Triptorelin is a prescription medicine. Chemically it is a synthetic decapeptide analog of gonadotropin releasing hormone (GnRH), supplied in the United States as triptorelin pamoate for intramuscular injection and administered by a healthcare professional rather than self administered. Two triptorelin products carry United States prescribing information: Trelstar (triptorelin pamoate for injectable suspension) and Triptodur (triptorelin extended release injectable suspension). Each product has its own approved indication, and the indication statement in the prescribing information is the only place where an approved use is defined. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, symptom or treatment decision.

The approved uses, as the United States labels word them

The two United States triptorelin labels define separate populations. The table below summarises the indication statements as they are worded in current prescribing information.

Nothing else appears in the indications sections of these two labels. Whether either indication applies to a particular person is a judgement for a prescribing clinician who has examined that person and reviewed the relevant testing.

Indication 1: palliative treatment of advanced prostate cancer

The Trelstar label frames the prostate cancer indication as palliative, meaning the goal described is disease control and symptom control rather than cure. The pharmacological aim is androgen deprivation: sustained exposure to a GnRH agonist desensitises pituitary GnRH receptors, after which luteinising hormone output falls and testicular testosterone production declines. Androgen directed therapy of this type has been a long standing backbone of advanced prostate cancer management, and a 29 year national analysis of prescribing and procedure data reported shifting long term trends in the use of androgen directed therapy for advanced prostate cancer, including the balance between surgical and medical castration (PMID 41518446).

Comparative safety information for this drug class comes in part from post marketing data. A 2025 real world pharmacovigilance study examined spontaneous adverse event reports for long acting GnRH analogs and reported that adverse event profiles differed among individual agents in the class rather than being identical across them (PMID 40644420). The study design was disproportionality analysis of reported events, which describes reporting patterns and does not establish incidence in any individual patient.

Indication 2: central precocious puberty in pediatric patients 2 years of age and older

The Triptodur label covers central precocious puberty, a condition in which the hypothalamic pituitary gonadal axis activates earlier than expected, producing early pubertal development and accelerated skeletal maturation. The labeled approach is the same receptor desensitisation used in oncology, applied so that gonadotropin output and sex steroid production are suppressed back toward prepubertal levels while a specialist monitors growth and pubertal staging. Treatment decisions, monitoring intervals and the timing of discontinuation are clinical judgements made by the treating endocrinologist.

The distinction between continuous and pulsatile GnRH exposure matters for understanding why one molecule can suppress an axis in one setting and stimulate it in another. Researchers comparing pulsatile GnRH therapy in male patients with pituitary stalk interruption syndrome and congenital hypogonadotropic hypogonadism reported that pulsatile delivery was used to drive gonadotropin secretion and gonadal response, with outcomes differing between the two diagnostic groups (PMID 35218954). Depot triptorelin products are designed for the opposite effect, continuous exposure leading to suppression.

How the labeled uses follow from the pharmacology

Both approved indications depend on lowering sex steroid levels by acting upstream at the pituitary. A review of single dose GnRH antagonist applications described how antagonists occupy the GnRH receptor and block gonadotropin release immediately, a pharmacological contrast with agonists, which first stimulate the receptor before desensitisation develops (PMID 10972518). That early stimulation phase is the reason prescribing information for GnRH agonists in prostate cancer discusses the transient rise in testosterone that can occur after the first administration and the clinical monitoring that accompanies it.

Regulatory history of the indications

United States approval of triptorelin pamoate began with the prostate cancer indication. Trelstar Depot was approved by the Food and Drug Administration in 2000 for the palliative treatment of advanced prostate cancer, and longer interval formulations of the same active ingredient were approved subsequently under the Trelstar name, each carrying the same palliative prostate cancer indication rather than a new one. A ready to mix delivery system was later approved for the same indication.

The pediatric indication came much later. Triptodur, a longer interval triptorelin extended release injectable suspension, was approved in 2017 for central precocious puberty in pediatric patients 2 years of age and older. Importantly, the two products are not interchangeable: each has its own prescribing information, its own approved population and its own administration requirements, and an approval granted to one product does not extend an indication to the other. Outside the United States, triptorelin is marketed under other brand names with broader approved indications in some jurisdictions, which is why international product information and United States prescribing information do not always match.

Research areas that are not United States label indications

Short factual note: the following uses appear in published trials and reviews but are not approved indications in current United States triptorelin prescribing information. They are listed here only so readers can place the literature in context.

• Endometriosis. A prospective, multicenter, randomized study reported that dienogest was as effective as triptorelin for the treatment of endometriosis after laparoscopic surgery (PMID 11937116), and a pharmacotherapy review summarised the evidence base for triptorelin in endometriosis management (PMID 24832495).
• Ovarian suppression in premenopausal breast cancer. Researchers reported long term outcomes among premenopausal patients with early breast cancer who received pharmacological ovarian suppression during chemotherapy (PMID 34850043).
• Fertility preservation during chemotherapy. A pediatric oncology report described triptorelin use for fertility preservation in adolescents treated with chemotherapy for cancer (PMID 29620680).
• Assisted reproduction protocols. A meta-analysis assessed the efficacy of the GnRH agonist nafarelin in assisted reproductive technology (PMID 11212082), and a multicenter pilot randomized controlled trial reported on random start progestin primed ovarian stimulation in oocyte donation as an alternative stimulation strategy (PMID 41373024).

None of the above changes the United States indication statements summarised earlier in this page.

Adverse Events With Long-Acting GnRH Agonists: What Studies Report

Published safety information for this class centres on the consequences of sustained sex steroid suppression plus agent specific reporting patterns. The 2025 pharmacovigilance analysis of real world reports compared long acting GnRH analogs and reported that the adverse event profiles differed among individual agents in the class (PMID 40644420). Spontaneous report databases capture what was reported to regulators and cannot establish causation or frequency.

Skeletal effects have received particular attention in settings where estrogen is suppressed. The randomized phase 3 HOBOE study reported bone mineral density changes with adjuvant tamoxifen, letrozole, or letrozole plus zoledronic acid in early stage breast cancer, with the bisphosphonate containing arm protecting against the bone loss seen with the aromatase inhibitor (PMID 22412041). A separate review examined the broader consequences of prolonged ovarian suppression and hypoestrogenism during breast cancer treatment, weighing those risks against the risk of recurrence (PMID 33529690). Reviews of triptorelin in endometriosis have likewise addressed the hypoestrogenic symptom burden associated with GnRH agonist therapy (PMID 24832495).

Product specific warnings, contraindications and monitoring requirements are set out in each triptorelin label and are reviewed by the prescribing clinician before and during treatment.

Questions that belong with a prescribing clinician

Approved indication statements describe populations, not individuals. Whether triptorelin is appropriate, which product and schedule apply, how treatment interacts with other medicines or conditions, what monitoring is needed, and when treatment should stop are all clinical decisions. A licensed physician, urologist or pediatric endocrinologist is the correct source for those answers, and no educational summary substitutes for that conversation.

Related reading

• Are peptides safe? What the literature reports

References

• Adverse event profile differences among long-acting gonadotropin-releasing hormone analogs: A real-world, pharmacovigilance study (PLoS One, 2025)
• Long-term trends in androgen-directed therapy in advanced prostate cancer: a 29-year national analysis (International Urology and Nephrology, 2026)
• Efficacy of Pulsatile Gonadotropin-Releasing Hormone Therapy in Male Patients: Comparison between Pituitary Stalk Interruption Syndrome and Congenital Hypogonadotropic Hypogonadism (Endocrine Practice, 2022)
• GnRH antagonist in single-dose applications (Human Reproduction Update, 2000)
• Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study (Fertility and Sterility, 2002)
• Triptorelin for the treatment of endometriosis (Expert Opinion on Pharmacotherapy, 2014)
• Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients (Journal of the National Cancer Institute, 2022)
• Triptorelin for Fertility Preservation in Adolescents Treated With Chemotherapy for Cancer (Journal of Pediatric Hematology/Oncology, 2018)
• Efficacy of nafarelin in assisted reproductive technology: a meta-analysis (Human Reproduction Update, 2001)
• Feasibility and efficacy of random-start progestin-primed ovarian stimulation: a multicenter pilot randomized controlled trial in oocyte donation (Reproductive Biology and Endocrinology, 2025)
• Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study (Annals of Oncology, 2012)
• Perils of prolonged ovarian suppression and hypoestrogenism in the treatment of breast cancer: Is the risk of treatment worse than the risk of recurrence? (Molecular and Cellular Endocrinology, 2021)